Navigation Links
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa Clinical Trial Results

First clinical Results Confirm Potential New Application of Key Product in AM-Pharma's Pipeline

BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced the positive clinical results of its Phase IIa Alkaline Phosphatase (AP) trial for patients with ulcerative colitis, a chronic and relapsing inflammatory bowel disease affecting the colon.

In this recent trial, AP was used in the treatment of 21 hospitalised patients suffering from moderate to severe ulcerative colitis, who had failed to show improvement using existing treatments of steroids and immunosuppressants. The AP therapy was administered through a duodenal drip at a dose of 10mg AP per day.

In the trial, patients showed clinically relevant improvement after the seven day treatment period, in the two main clinical parameters (Truelove-Witts and Mayo scores) measured three weeks after starting the AP trial.

Patient response rates after three weeks were 63% on the Truelove-Witts score and 47% on the Mayo score. Complete remission after three weeks was reached by 21% of patients on the Truelove-Witts score and by 5% of patients on the Mayo score. After 63 days, 79% of patients showed a response and 26% of patients were in complete remission according to the Truelove-Witts score. No serious adverse effects or treatment-related withdrawals were reported.

AP is a unique therapy for ulcerative colitis based on the dephosphorylation and detoxification of a group of bacterial endotoxins called lipopolysaccharides, which can cause inflammation in the colon. AM-Pharma's patented AP treatment has already shown positive results in trials for treatment of acute renal failure and sepsis.

Bart Wuurman, CEO commented: "It's fantastic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/29/2015)... PITTSBURGH , July 29, 2015  Mylan ... received regulatory clearance from the European Commission under the ... of Perrigo Company plc (NYSE: PRGO ; TASE).  ... Coury commented, "Today marks yet another important milestone ... and serves as further affirmation of the sound industrial ...
(Date:7/29/2015)... 29, 2015  Efforts to improve working capital efficiency ... firms in North America and ... an effective working capital management will ease the difficulties ... Big pharma companies expect to invest in optimizing working ... http://photos.prnewswire.com/prnh/20150724/241957LOGO Analysis from Frost ...
(Date:7/29/2015)... SEATTLE, Wash. , NEW YORK ... , July 29, 2015  CMC Biologics, a ... therapeutic proteins, and River Vision Development Corporation (River Vision), ... that they have entered into an agreement for ... (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like ...
Breaking Medicine Technology:Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 3Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 5Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 6Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 7Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 8Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 9Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 2CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 3
... 2011 , For the fourth year, the ... Awards for evidence-based psychosocial,interventions for people with dementia and ... better care and share best,practices. Applications can be submitted ... at http://www.alz.co.uk/award . Psychosocial research involves ...
... ClinStar, LLC, an established CRO providing clinical research ... Europe to the pharmaceutical and biotechnology industry, announced today ... East Coast of the United States. ... US location to its headquarters in San Francisco, CA, ...
Cached Medicine Technology:4th Alzheimer's Awards Announced in Search of Global Solutions for Better Dementia Care 2ClinStar, LLC Establishes New Office on the US East Coast 2
(Date:7/29/2015)... Angeles, CA (PRWEB) , ... July 29, 2015 ... ... to Honduras with the Hackett Hemwall Foundation in March, Steven W. Meier M.D., ... pro bono prolotherapy treatments to qualifying patients with demonstrated financial need. , “We ...
(Date:7/29/2015)... Mobile, AL (PRWEB) , ... July 29, 2015 , ... ... The directory will include the general contact information, website, types of plans administered, years ... submitted their business listing and have at least one plan with Employee Fiduciary. A ...
(Date:7/29/2015)... ... , ... TransFlip is an all new dynamic transition pack for FCPX, containing ... transitions are easy to apply and modify for any skill-level user. TransFlip includes custom ... styles, kinetic flipping panel animations are just a few clicks away. , TransFlip contains ...
(Date:7/29/2015)... ... July 29, 2015 , ... Toronto native Douglas James ... Dr. Cottrell has been making predictions about the economy, politics, social issues, as ... these prognostications. He warns that extreme weather conditions and increased earthquake / volcanic ...
(Date:7/29/2015)... ... July 29, 2015 , ... The Woodlands and Spring Fit Body Boot ... to worthy charitable causes each month. The new system will track each time a ... Check In at each facility, the boot camps will donate 20 cents to a ...
Breaking Medicine News(10 mins):Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3
... in Medicare, WASHINGTON, Sept. 14 - The ... state of,Mississippi,s Medicaid program $1.2 million per month ... IT. The savings and increased quality,demonstrated in Mississippi ... the Pharmaceutical Care Management Association,(PCMA) said today., ...
... no difference between the two protective treatments , FRIDAY, Sept. ... found that a pill called dabigatran etexilate (DE) is just ... risk of blood clots after total hip replacement surgery. , ... , the study included almost 3,500 hip replacement patients who ...
... 14 As a prostate cancer survivor, General,Colin Powell ... United States of,the importance of prevention. In 2003, ... and made a full recovery. Since that time, General ... Council, a non-profit,that each year sponsors Prostate Cancer Awareness ...
... white paper that examines various state initiatives to expand access ... and Congress in support of state efforts, was distributed today ... The paper, State Experimentation with Reforms to Expand Access to ... part of any state-based reform. It is a summary of ...
... Francisco will,get an early jump on the first national ... patient advocacy group, will be holding a,special show at ... two bands,will perform the best New Wave hits of ... The suggested donation is $10. More,information is available from ...
... Australian Geoff Thomas Just Isn,t Riding Across the United ... to Fulfill an Ambitious Goal, WASHINGTON, Sept. 14 ... week after making headlines throughout the,U.S. by cycling to ... says is the,first trip of its kind to raise ...
Cached Medicine News:Health News:E-Prescribing Saving Mississippi Medicaid $1.2 Million Per Month 2Health News:Pill Equals Injection in Preventing Clots After Hip Replacement 2Health News:General Colin Powell Speaks Out for Prostate Cancer Prevention 2Health News:Internal medicine physicians recommend key elements to guide state initiatives 2Health News:Internal medicine physicians recommend key elements to guide state initiatives 3Health News:San Francisco Psoriasis Event Tonight Will Celebrate First National Short Sleeve Day 2Health News:Bicyclist to Stop in DC during 9,000 Mile Lap Around the U.S. 2
... assays for the detection and ... extractable nuclear antigens (ENA) [RNP, ... (La)] in human serum. SS-A ... aid in the diagnosis of ...
... Inc. (DAI) ENA Profile Enzyme-Linked Immunosorbent Assay ... antibodies in human serum to individually coated ... and Jo-1 in a single serum specimen. ... be used as an aid in the ...
... immunoassay(EIA) test system for the detecton ... Sm, RNP, SSA, SSB, Scl-70 and ... from this assay can be used ... of autoimmune disease. This product is ...
... Inc. ENA Profile-6 ELISA test system is ... IgG antibodies to Jo-1, Sm, Sm/RNP, SSA, ... performed according to the directional insert, the ... in the diagnosis and treatment of autoimmune ...
Medicine Products: